Meet Our Featured Speakers

The mRNA industry is growing rapidly. Analysts predict that the global market will exceed USD$60 billion by 2030, driven by advances in vaccines, oncology, rare diseases, and personalised therapeutics. The next phase of expansion depends not only on progress but also on regulatory compliance and data integrity. Global regulators no longer view compliance as a box-ticking exercise, as it now serves as a central pillar of manufacturing, product release, and long-term patient safety.

In 2025, both the EMA and FDA updated their guidance on Quality by Design, potency assays, and comparability protocols for mRNA platforms. These revisions establish clear expectations for platform-based submissions, requiring that process understanding, potency validation, and drift monitoring be incorporated into every filing. The compliance environment now mandates immutable cloud-based batch records, traceable electronic signatures, and AI-flagged deviations as standard inspection criteria.

Across the globe, pharmaceutical and biotech companies continue to invest heavily in compliant digital infrastructure and scalable production platforms. The shift towards modular manufacturing and remote GMP audits is redefining the pace of production cycles. With standardisation and comparability shaping both progress and oversight, mRNA producers are reconfiguring their facilities to meet next-generation compliance requirements.

The core of the discussion lies in aligning scientific agility with regulatory predictability. The complexity of mRNA, from sequence modification to lipid nanoparticle encapsulation, requires meticulous documentation and real-time quality verification. Whether managing self-amplifying RNA strain updates, LNP characterisation, maintaining LNP stability limits, or preparing for remote GMP inspections, compliance has emerged as a strategic advantage for companies operating within the global RNA landscape.

The mRNA era is defined not only by therapeutic potential but also by confidence in product quality, continuity of compliance, and cooperation across borders. The path forward requires a balance between progress and integrity, where compliance serves as both a safeguard and an enabler of the next generation of RNA medicines.

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.